What's more, as the U.S. IPO market heats back up, more of these deals could follow, said Angelo Bochanis, an analyst at Renaissance Capital, a provider of pre-IPO research and IPO-focused ETFs.

With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...

Shares of Palantir Technologies (NASDAQ:PLTR) gained 6.43% over the past five trading sessions, continuing a rally that has seen the stock rise 114.59% over the past six months. Since its October 2022 ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Welcome to Ask the analyst, where I put questions from Morningstar readers (and myself) to members of our equity research team. If you have a question about an ASX company or industry that we cover, ...

Geely delisted its premium subsidiary Zeekr from the New York Stock Exchange after just one year and offers 2.4 billion ...

IN RECENT weeks, two relatively large initial public offers (IPOs) were announced: NTT’s data centre real estate investment ...

Transatlantic dealmaking is reshaping the UK’s corporate landscape, as global firms capitalise on an opportunity to improve ...

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...

More companies are confidentially filing DRHPs as they prefer gauging investor interest and market conditions before going ...

Rational investors have abandoned CBA, resulting in a share price that gets 'pushed around' by passive and momentum flows.

Institutional demand has been fuelling Bitcoin’s comeback, potentially shifting crypto from speculation to strategic investment.